Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
22 avr. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
17 avr. 2024 01h15 HE
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
15 avr. 2024 14h00 HE
|
Novartis Pharma AG
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare...
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
06 avr. 2024 16h16 HE
|
Novartis Pharma AG
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant...
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
22 mars 2024 07h22 HE
|
Novartis Pharma AG
Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy1-5 If...
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
21 mars 2024 09h00 HE
|
Sandoz Group
MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in EuropeAdditional manufacturing area of 3,000m2...
Sandoz receives FDA approval for first and only denosumab biosimilars
05 mars 2024 13h24 HE
|
Sandoz Group
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®*...
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
05 mars 2024 09h22 HE
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre genehmigten die 27. Dividendenerhöhung in Folge auf CHF 3,30 (+3,1 %) pro Aktie für 2023. Dies entspricht einer Rendite von 3,7%1 und einer Ausschüttung von rund 58%...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
05 mars 2024 09h22 HE
|
Novartis Pharma AG
Les actionnaires approuvent la 27e augmentation consécutive du dividende qui passe à CHF 3,30 (+3,1%) par action pour 2023 ; représentant un rendement de 3,7%1 et une distribution du free cash-flow...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
05 mars 2024 09h22 HE
|
Novartis Pharma AG
Shareholders approve 27th consecutive dividend increase to CHF 3.30 (+3.1%) per share for 2023; representing a 3.7% yield1 and approximately 58% payout of free cash flowShareholders confirm Joerg...